142 filings
8-K
MRTX
Mirati Therapeutics Inc
23 Jan 24
Contingent Value Rights Agreement
8:48am
8-K
MRTX
Mirati Therapeutics Inc
19 Dec 23
Other Events
7:30am
8-K
MRTX
Mirati Therapeutics Inc
13 Dec 23
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
MRTX
Mirati Therapeutics Inc
24 Nov 23
Other Events
4:45pm
8-K
MRTX
Mirati Therapeutics Inc
13 Nov 23
Other Events
12:00am
8-K
tiazn7
6 Nov 23
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
8:05am
8-K
hpfp0m81h7v a4nt4ut
10 Oct 23
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
7:33am
8-K
aytxpfgiyer d6p2
23 Aug 23
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
4:01pm
8-K
hpq6xy98n a401ihzqv0
9 Aug 23
Mirati Therapeutics Announces Proposed Public Offering
4:40pm
8-K
y6ob9ivgz5yi
8 Aug 23
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
4:01pm
8-K
f056ijql4dcs1f8
21 Jul 23
Other Events
6:05am
8-K
21tk 8i1qoqj63wh
23 Jun 23
Departure of Directors or Certain Officers
4:02pm
8-K
01ticp8dn1dj0eh7po0p
24 May 23
Other Events
4:09pm
8-K
1ponwzoe3qupv09mr59
12 May 23
Departure of Directors or Certain Officers
4:02pm
8-K
9u6oq60pdz3g7iy04bo
9 May 23
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
4:06pm
8-K
oqiqvmhw60g2ghps7g
28 Feb 23
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
4:08pm
8-K
unhk4hu rton
9 Jan 23
Results of Operations and Financial Condition
1:06pm
8-K
jzg5n6yru9
12 Dec 22
Other Events
8:22pm
8-K
wa83x3
5 Dec 22
Other Events
7:00pm
8-K
iep5ie7m
2 Dec 22
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
8:01am